men in Biological Technology

PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study

- Study Meets Primary Endpoint Showing Statistically Significant Improvement in Overall Survival - - First Active Immunotherapy for Cancer to Prolong Survival - - Full Data to be Presented at Plenary Session at Upcoming AUA Annual Meeting - - Company to Host a Conference Call Today ...

Growing Generations Announces Surrogacy Program for Men with HIV

LOS ANGELES, June 3 /PRNewswire/ -- Growing Generations, the nation's largest surrogacy agency, has launched a new program that provides surrogacy and egg donation services to men with HIV and allows them to use their own sperm to create biological families. The new program is made possible ...

When to Wait and When to Treat? New Program Will Search for Biomarkers in Men With Prostate Cancer to Help Find an Answer

SEATTLE, May 2 /PRNewswire/ -- Researchers at Fred Hutchinson Cancer Research Center have a lead role in a new public/private partnership to create the first systematic surveillance program of men with prostate cancer to look for biological clues to help determine when to wait and when to trea...

deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women

REYKJAVIK, Iceland, Jan. 31 /PRNewswire-FirstCall/ -- Scientists from deCODE genetics (Nasdaq: DCGN ) today report the discovery of two common, single-letter variants in the sequence of the human genome (SNPs) that regulate one of the principle motors of evolution. Versions of the two SNPs, l...

Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States

CHARLIE ROSE SCIENCE SERIES Episode #9 - HEART DISEASE September 19, 2007 NEW YORK, Sept. 14 /PRNewswire/ -- The following is being issued by Pfizer Inc: WHAT: The upcoming episode of the Charlie Rose Science Series will discuss the global burden of cardiovascular disease, the leading...

Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress

...gene signatures of male patients for whom the Oncotype DX breast cancer test was used to guide chemotherapy treatment indicating that breast cancer in men displays similar gene signatures to female breast cancer. Study results demonstrating that there were significant differences in gene expres...

Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting

...e current treatment options share the common goal of saving and redistributing existing hairs," said Dr. Craig Ziering. "For the millions of men and women who grapple every day with their hair loss, the results of our HSC trial indicate the potential for a phenomenal treatment option that stimu...

Novel gene found for dilated cardiomyopathy

... ways. In DCM the major pumping chamber of the heart, the left ventricle, is dilated, often without any obvious cause. DCM occurs more frequently in men than in women and is most common between the ages of 20 and 60 years, although it also occurs in fetuses, newborns and children. About one in three c...

Johnson & Johnson Completes Acquisition of Cougar Biotechnology

...studying abiraterone acetate in patients with metastatic, castration-resistant prostate cancer who have yet to receive chemotherapy. One in six men will be diagnosed with prostate cancer in his lifetime, and the disease accounts for 10 percent of cancer-related deaths in the United States. C...

Bay Area Youth to Represent ALS Patients at Giants' and Angels' Baseball Games on July 4th

...to have an opportunity to know him and have his family's support for our work. It is heartbreaking that there is so little that can be done for young men and women like Corey today. That is unacceptable, and we must not stop until we have a better answer for all ALS patients," said Steve Perrin, Ph.D., ...

Remuda Ranch Programs for Eating and Anxiety Disorders Reports Need for Increasing Awareness of Eating Disorders in Males

...en not available to the male population. (Logo: http://www.newscom.com/cgi-bin/prnh/20090604/CG27861LOGO "It is a reality that boys and men do have eating disorders and ignoring the problem may only allow it to get to a life threatening state," said Sam Lample, therapist and assistant clin...

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa

... or eggs, with the fallopian tubes or the uterus, endometriosis, frequent miscarriage, as well as hormonal and autoimmune (antibody) disorders in both men and women.(8) With infertile couples, the source of infertility lies with the male in 40 percent of cases and 40 percent with the female. The re...

deCODE Discovers a Gene Linked to Risk of Kidney Stones and Osteoporosis

...gh urination, though larger ones can block the urinary tract, causing considerable pain and bleeding. Kidney stones affect some 5% of women and 10% of men in the industrialized world. Larger stones can be detected with ultrasound screening and broken up to facilitate passage, though the recurrence rate i...

OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer

...etter positions the availability of OGX-011 treatment to a larger number of men with prostate cancer." The Phase 3 trial has been designed in collaborati... revised trial will be a randomized, controlled, international study in 800 men with metastatic CRPC who are in need of first-line chemotherapy. Patients w...

Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August

...ment at Amgen. "Likewise, there is currently no approved treatment for the men and women receiving hormone ablation therapy for prostate or breast cancer ...uced Bone Loss In the U.S., prostate cancer is the most common cancer in men and breast cancer is the most common cancer in women. It is common for pros...

SEP Signs REGURIN(R) Deal

...eted under different brand names in European countries including Germany, Italy, Austria, Spain and Switzerland. Regurin is licensed for use in men and women to treat the symptoms of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder (...

AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule

...nt of the prostate, affecting more than 20 million men in the U.S. alone. "We are very pleased to have ... (BPH) is one of the most common diseases of aging men - affecting more than 20 million men in the United States - but its etiology is far fro...

AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia

...nt of the prostate, affecting more than 20 million men in the U.S. alone. Sanofi-aventis U.S. LLC entered... (BPH) is one of the most common diseases of aging men - affecting more than 20 million men in the United States - but its etiology is far fro...

CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share

...s and markets proprietary ICG sensors. The Company's ICG Systems are being used by physicians around the world to help battle the number one killer of men and women -- cardiovascular disease. Partners include GE Healthcare, Philips Medical Systems and Mindray. About SonoSite SonoSite, Inc. ( ww...

Biotech Shows Glimmer of an Upward Trend

...by a whopping 440 percent since the company first announced it had positive Phase III data that showed its lead product Provenge extended the lives of men with advanced prostate cancer by an average of 4.1 months. According to analysts, Dendreon should be able to file for regulatory approval during the f...

Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients

...etuximab is appropriate for a patient before administering the biologic. Colorectal cancer is the second leading cause of cancer-related deaths among men and women in the United States. "We are very pleased with the results of this study and the potential ChemoFX has to help physicians find the rig...

Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting

...01 in combination with docetaxel and prednisone in men with castrate-resistant prostate cancer (CRPC)(1)....nother presentation reported data from a cohort of men with docetaxel-refractory prostate cancer who were...mbination with docetaxel (D) and prednisone (P) in men with castrate resistant prostate cancer (CRPC). A...

RSCI Announces World-Leading Stem Cell Science Advisory Board

...is the only doctor known to have a successful stem cell therapy for renal problems. "To summarize," said Mr. Margolis, "these five men have improved the lives of more 'untreatable' patients than all of the world's thousands of embryonic doctors and scientists combined---and that will ...

Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.

...al is studying abiraterone acetate in patients with metastatic, castration-resistant prostate cancer who have yet to receive chemotherapy. One in six men will be diagnosed with prostate cancer in his lifetime, and the disease accounts for 10 percent of cancer-related deaths in the United States. ...

VIVUS Reports First Quarter 2009 Financial Results and Highlights

...February 2009, we announced that we had initiated the REVIVE-Diabetes (TA-302) study to evaluate avanafil for the treatment of erectile dysfunction in men with diabetes, one of the most common causes of erectile dysfunction. "Our pivotal phase 3 trials for both Qnexa for the treatment ...

Dendreon Reports First Quarter 2009 Financial Results

...erein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FD...

Biotech Drops on Weaker First Quarter Drug Sales, But Broader Markets Remain on a Roll

...es doubled following the detailed study results for its prostate cancer treatment candidate Provenge, which met its goal of prolonging the survival of men with prostate cancer. The Burrill Report also found that: 135 public biotech companies are trading with less than one year of ca...

OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer

...stian Hotte at Juravinski Cancer Centre, in Hamilton, Ontario, Canada. This will be a randomized, controlled, international trial in approximately 300 men with metastatic CRPC who responded to first-line docetaxel therapy, but subsequently have progression of disease, including prostate cancer-related pa...

Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting

...blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC)." AU...ROVENGE(R) (sipuleucel-T), Dendreon's investigational product candidate for men with advanced prostate cancer representing the first in a new class of acti...

Lotus Scarless Hair Transplantation (International) Medical Chain Institute Opens New Center on Beijing's Prestigious Chang'An Avenue

...leaving patients to enjoy their natural looking hair. According to statistics, there are about 134 million alopecia patients in China, in which men account for 74.8%. With the increase of stress in people's daily life, baldness is increasingly serious, and has become a barrier to employment and m...

Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer

...54 upregulation and peripheral immune responses in men enrolled in the trial. PROVENGE or placebo w...regulation in APCs is maintained after boosting in men with androgen-dependent prostate cancer," said Dav...is consistent with that observed in our studies of men with androgen-independent disease where the cumula...

Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

...o to three percent of the world's population, and approximately one out of three patients affected by psoriasis may develop psoriatic arthritis. Both men and women are equally affected by psoriatic arthritis, most commonly between the ages 30 and 50, in the peak of their productive years. About ...

Heart Hospital of Austin First Site in World to Test Efficacy of New Adult Stem Cell Therapy to Treat Damaged Heart Tissue in Phase II Trial

...k : In 2009 alone, more than half a million Americans will have their first attack. According to the American Heart Association, 18% percent of men and 35% of women will have another heart attack within six years of their event. ...

Batman Teams with Senator Katherine Laforge to Help Free America from OPEC

...e oil industry has become American’s shadow government complete with free use of our arm forces to protect its products and profits. Our service men and women die to protect their profits, and billions in tax dollars are used to support their industry.” “It is a very gloomy assessment...

Heart Disease: An Epidemic For Firefighters

...g their services free of charge. "There are tremendous costs associated with early deaths of our first responders in every community as we lose men and women in their 30s, 40s and 50s who are our first line of defense but who don't live to perform their jobs for very long," says Chief Rolader. "W...

Prometheus Receives New York State Approval for PROMETHEUS(R) IBS Diagnostic, First Blood Test for Irritable Bowel Syndrome

... 20%, of the U.S. population had symptoms of IBS, making it one of the most common disorders diagnosed by physicians. At least twice as many women as men are affected by IBS, a disorder characterized most commonly by cramping, abdominal pain, bloating, constipation and diarrhea. Although it significant...

Dendreon Reports Fourth Quarter and 2008 Year End Financial Results

...investigational active cellular immunotherapy PROVENGE(R) (sipuleucel-T) in men with androgen-independent prostate cancer. While Dendreon remains blinded ...ct to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the pre...

BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University

... under the direction of NHLBI to study the development of cardiovascular disease over time. When FHS started it recruited an Original Cohort of 5,209 men and women between the ages of 30 and 62 from the town of Framingham, Massachusetts, who had not yet developed overt symptoms of cardiovascular disease...

AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results

...et in collaboration with our partner, sanofi-aventis. We believe that this compound could prove to be a novel treatment for the benefit of millions of men with BPH and also build value for our shareholders." Dennis Turpin, Senior Vice President and Chief Financial Officer of AEterna Zentaris added, "Th...

OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009

...GX-011 in combination with docetaxel as second-line chemotherapy in men with CRPC, via the SPA process. In a letter from the FDA responding...GX-011 in combination with docetaxel as second-line chemotherapy in men with CRPC. OncoGenex has revised the protocol based on the FDA's re...